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Background: Tumor models are critical for our understanding of cancer and the development of cancer
therapeutics. Here, we present an integrated map of the genome, transcriptome and immunome of an epithelial
mouse tumor, the CT26 colon carcinoma cell line.
Results: We found that Kras is homozygously mutated at p.G12D, Apc and Tp53 are not mutated, and Cdkn2a is
homozygously deleted. Proliferation and stem-cell markers, including Top2a, Birc5 (Survivin), Cldn6 and Mki67, are
highly expressed while differentiation and top-crypt markers Muc2, Ms4a8a (MS4A8B) and Epcam are not. Myc, Trp53
(tp53), Mdm2, Hif1a, and Nras are highly expressed while Egfr and Flt1 are not. MHC class I but not MHC class II is
expressed. Several known cancer-testis antigens are expressed, including Atad2, Cep55, and Pbk. The highest expressed
gene is a mutated form of the mouse tumor antigen gp70. Of the 1,688 non-synonymous point variations, 154 are
both in expressed genes and in peptides predicted to bind MHC and thus potential targets for immunotherapy
development. Based on its molecular signature, we predicted that CT26 is refractory to anti-EGFR mAbs and sensitive
to MEK and MET inhibitors, as have been previously reported.
Conclusions: CT26 cells share molecular features with aggressive, undifferentiated, refractory human colorectal
carcinoma cells. As CT26 is one of the most extensively used syngeneic mouse tumor models, our data provide a map
for the rationale design of mode-of-action studies for pre-clinical evaluation of targeted- and immunotherapies.
Keywords: Immunotherapy, Cancer models, Computational immunology, Colorectal cancerBackground
Murine CT26 (Colon Tumor #26) cells were developed in
1975 by exposing BALB/c mice to N-nitroso-N-methylur-
ethane (NMU), resulting in a rapid-growing grade IV carcin-
oma that is easily implanted and readily metastasizes [1]. Used
in over 500 published studies, the CT26 colon carcinoma is
one of the most commonly used cell lines in drug develop-
ment. Numerous cytotoxic agents as well as therapeutics tar-
geting specific signaling pathways have been studied with
these cells [2-4]. Moreover, as the CT26 model in BALB/c
mice provides a syngeneic in vivo test system, it is frequently
used for developing and testing immunotherapeutic concepts.* Correspondence: john.castle@tron-mainz.de; sahin@uni-mainz.de
1TRON gGmbH - Translational Oncology, Johannes Gutenberg-University
Medical Center gGmbH, Langenbeckstr. 1, Building 708, 55131 Mainz, Germany
2University Medical Center of the Johannes Gutenberg-University Mainz,
55131 Mainz, Germany
Full list of author information is available at the end of the article
© 2014 Castle et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.In sharp contrast to its frequent use in drug development,
there have been no comprehensive studies of the genome
and transcriptome of CT26. Kras is mutated in CT26 [5] but
other mutations are not known. Mutations in Cdkn2a, Mek,
Braf and Pi3k in combination with Egfr and Vegf expression,
for instance, may influence the results of pre-clinical investi-
gations of treatment modalities. Moreover, while gp70, the
product of the envelope gene of murine leukemia virus
(MuLV)-related cell surface antigen, is a known model anti-
gen for studying antigen-specific immune responses in the
CT26 system, there is no comprehensive knowledge of po-
tential tumor antigens in this cell line system.
Further, the lack of comprehensive data on the murine
CT26 colon cancer data sharply contrasts to the extensive
molecular characterization of human colorectal cancer
(CRC). As a group, human CRC is highly heteroge-
neous with multiple evolutionary paths, with moleculartd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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carcinoma. Many human CRC genomes are now known
and multiple molecular signatures, classifications and bio-
marker concepts are published [6-9]. As comprehensive
genomic and transcriptomic data of CT26 has not been
available, it is unclear how CT26, a chemically-induced
tumor, molecularly correlates to human CRC subtypes
and to what extent it may be used as model.
To answer these questions, we utilized next-generation
sequencing, bioinformatics and immuno-informatics to
create an integrated mouse solid tumor mutanome, tran-
scriptome and immunome, providing an overdue analysis
of the CT26 cancer cell line.
Results and discussion
The CT26 tumor genome: using the NGS reads, we



















Figure 1 The CT26 Genome. A) Circos diagram showing (outer to inner):
number. Black: deleted; green: haploid; yellow: diploid; dark purple: triploid
red: higher copy number. Track 2: High confidence point mutations, plotte
allele frequency 100. Colors are blue (0–40), green (40–60), orange (60–90),
missense mutations. Mutations in peptides likely to bind MHC are colored
according to allele frequency. B) DNA gene copy number. C) Single nucleo
mutation. D) Mutation classification.comparing CT26 to BALB/cJ DNA. We determined abso-
lute DNA copy number using the ratio of exome-seq reads
mapping to each gene from CT26 versus those from BALB/
cJ, and integrating variant allele fraction (Figure 1A, outer
ring). We found that the ploidy of CT26 is strikingly large
with large regions of triploidy and tetraploidy, in agreement
with previous karyotyping results [10]. The median and
mean copy number in average across all genes is 3 and 3.5,
respectively, with 8,686 genes in triploid regions (45% of the
genes) and 7,448 (39%) in tetraploid regions (Figure 1B). No
reads map to the Y chromosome (DNA or RNA), suggesting
that CT26 cells originated from a female mouse. Only one
homozygous deletion was found, which contains the tumor
suppressor Cdkn2a (cyclin-dependent kinase inhibitor 2A;
Ink4a) locus on mouse chromosome 4.
We identified 3,023 high-confidence single nucleotide
variations (SNVs; Figure 1A, 2nd ring) and 362 shortSingle nucleotide mutations
  in transcripts 3023
    in UTRs 629
    in CDS 2394
       synonymous 706
       non-synonymous 1688
  missense 1620
  premature stop 68











































cytogenetic bands in black, gray and white. Track 1: DNA copy
; light purple: tetraploid; dark blue: pentaploid; bright blue: hexaploid;
d based on DNA allele frequency. Inner is allele frequency 0, outer is
and red (90–100). Track 3: predicted MHC binding IC50 scores for
orange (IC50 < 500 nM). Track 4: insertions and deletions plotted
tide mutation changes and the nucleotide immediately 3′ of the
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Indels are dominated by A/T deletions (44%). We se-
lected high confidence SNVs in exons (3,023; Figure 1D),
the majority of which are localized in coding regions
(2,394; 79%). Of the SNVs in coding regions, the major-
ity (1,688; 71%) cause non-synonymous protein changes,
including 1,620 missense and 68 nonsense variants. The
CCDS database identifies 32 million protein-encoding
nucleotides in the mouse genome. Relative to a 2011
BALB/cJ genome, the CT26 variation rate in coding re-
gions is 53 non-synonymous and 22 silent mutations per
Mb. This is significantly more than the average found in
spontaneous human tumors (4 mutations per Mb) but
still within the range observed for primary human CRC
tumors, which ranges from less than 1 per Mb to over
100 mutations per Mb [11].
The identified SNVs represent variations between the
CT26 genome, derived from a BALB/c mouse in 1975,
and a BALB/cJ mouse in 2011. As such, the SNVs in-
clude both somatic mutations associated with the CT26
onco-transformation and genetic drift in the BALB/c
genome. We found 40,000 mouse SNPs that distinguish
the BALB/cJ and mm9 (C57BL/6) exomes. Of these, only
1.6% show a discrepancy between the CT26 and 2011
BALB/cJ genomes. Thus, while this does not eliminate
genetic drift or conclusively identify the substrain that
gave rise to CT26 cells, it demonstrates that the genome
of the mouse that originally created the CT26 cells is
similar to that of the current BALB/cJ mouse.
Spontaneous human CRC tumors contain primarily C >
T/G > A SNVs [12]. Of the 3,023 SNVs in the CT26 gen-
ome, 2,313 (77%) are transitions, of which most (1,980,
66%) are C > T/G > A mutations (Figure 1C), similar to
the human CRC mutation profile. Based on data from
over 7,000 human tumors, G is the dominate nucleotide
immediately 3′ of the mutated nucleotide in human CRC
tumors (CG >TG mutations) [11]. Conversely, we found
that CT26 SNVs are depleted in CG > TG and CA >TA
mutations and enriched in CT > TT and CC >TC muta-
tions. This pattern, a C > T mutation followed by a pyrimi-
dine, is found in tumor samples from human patients pre-
treated with temozolomide, an alkylating anticancer drug
[11]. CT26 was originally induced by the alkylating agent
NMU. That temozolomide and NMU are both are associ-
ated with tumors enriched in C > T mutations at positions
followed by a pyrimidine suggest a similar mutagenic pat-
tern for these two alkylating agents.
Of the 3,023 CT26 SNVs, 296 (10%) are homozygous or
heterozygous (100% allele frequency, Figure 1A, 2nd ring),
even in amplified regions with high copy number. Homo-
zygous variants cluster across chromosomes 6, 13, 14, 15,
and X. These regions could be the result of either a loss of
heterozygosity (LOH) onco-transformation or genetic drift
in a BALB/c mouse followed by inbreeding. If the result ofan onco-transformation, that the regions experienced
LOH, followed by mutations and copy number amplifi-
cation suggests that resulting individual alleles were
amplified 2-fold (chr X), 3-fold (chr 14), 4-fold (chr 6),
and 5-fold (chr 15).
We further investigated chromosome X. Mutations
occur on chromosome X with 100% and 50% DNA al-
lele frequency, suggesting that chromosome X is dip-
loid in CT26 cells. Female cells typically express XIST
and inactivate one X allele. In CT26, the RNA-Seq
data show that XIST is not expressed and, examining
the allele expression of heterozygous mutations, that
transcription occurs from both chromosome X alleles.
These findings are concordant with a scenario where
the chromosome X experienced both a loss of the inacti-
vated allele and an amplification of the non-inactivated al-
lele (occurring in either order).
In summary, the data imply that the CT26 has a com-
plex genome of high ploidy which underwent several
amplification events. Relative to a 2011 BALB/c genome,
the number of mutations is higher than average, with
many non-synonymous mutations. The mutation pattern
reflects the treatment with the NMU alkylating agent, a
similar but distinct pattern than found in spontaneous
primary CRC.
CT26 SNVs in onco-relevant genes: we investigated
whether mutations associated with CRC [12-14] are also
prevalent in CT26. APC, KRAS and TP53 are frequent
drivers of the linear and uniform evolution of spontan-
eous human CRC; of these, only Kras is mutated in
CT26. The CT26 Kras genomic locus is triploid and all
alleles contain V8M (located in a small molecule binding
site [15]) and G12D (known to stimulate proliferation)
mutations.
Several CRC subtypes are linked to syndromes based
on inherited gene defects and mutations. Genes associ-
ated with familial CRC (e.g., HNPCC, Lynch Syndrome,
FAP, Peutz-Jeghers) include mismatch repair genes
Mlh1, Mlh2, Mlh6, Msh2, Myh, Pms1, Stk1, Mutyh and
Ctnnb1. None are mutated in CT26. The lack of muta-
tions in mismatch repair genes Mlh1 and Msh2, which
are associated with CRC microsatellite instability (MSI),
agrees with the lack of mutation in Braf, which is fre-
quently associated with the MSI-high phenotype [16].
Further, the tumor suppressor Cdkn2a is homozygously
deleted and the genomic Mapk1 (MEK) and Met loci are
amplified in CT26. CRC-associated genes Fbxw7, Pik2ca,
Pten, Smad2, Smad4, Tcf7l2 are not mutated. Non-
synonymous point mutations occur in other CRC genes
Brca2 (R2066K), Pdgfra (V103I), Nav3 (V154I, S334N),
Atr (H792Q), Cdk8 (S87F), and Rel (A406T). Mutations
in cancer-related genes include mTor (V971M), Birc2
(E395K), Casp4 (H84Y), Cenpe (A834V), Esr1 (P508S),
Hdac2 (P228S), Ins1 (Y40C), Insr (A493V), Muc1
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(S107F), Ddr2 (A161V), Notch1 (R365S) and Rhoj
(L137F). Frameshift-causing indels occur in oncogenes
Ewsr1 (at amino acid 629) and Mpp3 (at amino acid 91).
CT26 gene expression: we generated gene expression
profiles from CT26 cells. Cancer-relevant genes such
Nras, Vegfa, Trp53 (TP53), Myc, Mdm2, and Hif1a are
expressed at high levels in CT26 (Figure 2, left). Egfr
and Flt1 are not expressed. Gene expression in CT26
relative to normal colon was used for pathway enrich-
ment analysis in order to identify broadly enriched path-
ways (Figure 3). Not surprisingly, the identified pathways
relate to cell proliferation (cell cycle phases and transi-
tions, DNA replication) and increased translation (pro-
tein and RNA metabolism). We examined individual
gene sets enriched in CT26 (Figure 4). Most enriched is
“CELL_CYCLE_RB1_TARGETS”, a gene set curated
from a study examining RB1 target genes involved in cell
cycle regulation [17], reflecting over-expression of all
Rb1 target genes (Figure 4B). Rb1 mRNA is itself 8-fold
up-regulated. Ezh2, downstream of the Egfr-ras-raf path-
way, impacts DNA methylation, promotes EMT and is
associated with poor prognosis in CRC [18,19]. Together
with its target genes, Ezh2 is over-expressed in CT26
cells. Mechanistically, that Rb1, Ezh2, Lin9, and E2f
mRNAs and their target genes are over-expressed sug-



























Figure 2 Gene expression of onco-relevant genes, stem cell and proli
epithelial markers, and differentiation markers in CT26 and mouse co
CT26 triplicates and the six normal colon samples (triplicates of one male aaddition to post-translational modifications, play a crit-
ical role controlling activation of each pathway.
The gene set associated with genes down-regulated
after Foxo3 up-regulation was found to be up-regulated
(Figure 4E). In agreement with this, Foxo3 is signifi-
cantly down-regulated in CT26 cells. Foxo3 expression
has been identified as a potential biomarker for CRC out-
come [20], with low Foxo3 associated with 2-fold shorter
survival. The low Foxo3 expression, the high Ezh2 expres-
sion and the enrichment of the “melanoma metastasis”
gene set [21] are all in line with the aggressive and high
metastatic activity of CT26 cells.
Differentiation markers further corroborate that CT26
cells are in a highly proliferative, undifferentiated state.
The “undifferentiated cancer” gene set is highly up-
regulated in the CT26 cells (Figure 4A). Stem cell markers
Cldn6 and Sox2 are highly expressed while differentiation
markers Muc2 and Ms4a8a (human MS4A8B) [22]
markers are not expressed (Figure 2, right). Whereas
Lgals1 (Galectin-1) is over 30-fold up-regulated in CT26
cells, the orthologous gene Lgals4 (Galectin-4), a differen-
tiation marker, is over 500-fold down-regulated in CT26
cells. The proliferation markers Top2a (DNA topoisomer-
ase 2-alpha), Mki67 and Birc5 (Survivin) are all highly
expressed in CT26 cells.
Epcam marks epithelial cells and colon crypt tops [23]
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FDR q-value = 0
Figure 3 Reactome pathways over-expressed in CT26 versus normal colon. Enriched Reactome pathways are displayed using Cytoscape ClueGO.
Ribosomal associated genes are over-expressed in CT26; while they are part of the influenza gene set, we posit their over-expression reflects increased
translational activity rather than an influenza-related process. For each gene set, Cytoscape ClueGo calculates a false-discovery rate statistic (FDR q-value)
reflecting the likelihood of the given enrichment by chance: the pathways listed in the table those with a zero q-value. Each dot in the image represents
a separate Reactome gene set. Gene sets with common members are placed proximally, grouped into common themes, colored the same and labeled.
Q-values for enriched pathways, Cytoscape settings and gene membership are in the supplementary information.
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highly expressed in normal colon but not expressed in
CT26. CD44 marks the crypt bottoms and is 18-fold up-
regulated. Silencing of WNT targets such as ASCL2,





























D.Cell cycle RB1 targets Mitosis LIN9 targets
EZH2 targets
Figure 4 Gene sets over-expressed in CT26 versus normal colon. A). T
from literature and overexpression was determined using GenePattern [47]
the GenePattern enrichment plot showing the enrichment plot (green) and
ranked-ordered list (black vertical lines). The plot on the right (blue bars) sh
(D), FOXO3 (E) and E2F1 (F).promoter methylation and associated with poor progno-
sis and increase metastatic spread [25]. In CT26,
Wnt10a is highly up-regulated but WNT target genes,
with the exception of Birc5, are not expressed. These


































he top 10 over-expressed gene sets. Gene sets included those curated
. B-F): gene set enrichment for the targets of specific genes, including
the location of the individual gene set members in the expression
ows the expression of the targeting gene RB1 (B), E2H2 (C), LIN9
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metastasize [26,27].
CRC cohort studies have identified markers for classify-
ing patient CRC tumors (Additional file 1: Table S8). The
three-group CRC classification platform using differenti-
ation marker KRT20 and “top crypt” markers CA, MS4
A12 and CD177 [6] classifies CT26 as a tumor with a less
mature phenotype and worse progression. The classifica-
tion platform using genes FRMD6, ZEB1, HTR2B and
CDX2 [7] classifies CT26 as the “CCS3” sub-type, with
poor prognosis, low therapy response and resistance to
cetuximab. The 7 gene “CRCassigner-7” platform [8] clas-
sifies CT26 cells as either “stem like” or “CR-TA” (cetuxi-
mab-resistant transit-amplifying).
The CT26 cancer immunome: immunotherapy concepts
include targeting tumor-specific antigens presented on
MHC molecules. We determined that CT26 cells have the
same MHC types as the parental BALB/cJ mice: H-2Dd,
H-2Kd and H-2Ld (class I) and H-2lad (class II). This is ex-
pected and a useful confirmation of the BALB/c-CT26 lin-
age, given on-going reports of cell line mis-identifications.
Class I loci H-2Dd and H-2Kd are expressed at levels com-
parable to normal tissues (Figure 5), lower than lymph
node and spleen but higher than non-immune tissues (e.g.,
heart, kidney, brain). B2m, part of the MHC class I com-
plex, is highly expressed. Both suggest that MHC class I is
functional. Normal tissues show variable expression of
MHC class II (e.g., lymph node and spleen are high, colon
expresses at 150 RPKM and brain is low but non-zero).
CT26 cells express neither MHC class II (0 RPKM) nor
the MHC class II transactivator Ciita, suggesting that
CT26 cells do not have functional MHC class II antigen
presentation.
Genes with tumor-associated expression as well as genes
with somatic mutations may act as tumor-associated anti-















CT26 triplicates Lymph node & spleen Other tissues
Figure 5 MHC class I (H-2D, H2-K, H-2 L) and class II (H2-IA)
expression in normal mouse tissues and CT26 cells. The normal
tissues are from both C57BL/6 J and BALB/c. The C57BL/6 J genome
does not have the H-2 L locus.protein of from a MuLV-related retrovirus) is a classical
model tumor antigen frequently exploited when using
CT26 system to investigate CD8 T cell immunity [28]. Ex-
pression of gp70 in normal mouse tissues has been ob-
served in mice over 8 months old [29,30]; however, gp70
levels are strikingly high levels in murine tumor cell lines
including CT26 [31]. Indeed, our data show that gp70 has
the highest expression of all CT26 genes. While gp70
DNA was not captured by the NGS exome-capture, we
were able to determine the gp70 sequence using the
RNA-Seq reads, averaging over 5,000x coverage due to the
high expression (Table 1, Additional file 1). Relative to the
gp70 sequence in the mm9 genome, the CT26 gp70 se-
quence falls in a CT26 tetraploid region and has 9 non-
synonymous mutations, including 3 homozygous and 6
heterozygous variants. Two variants are in dbSNP while
three are found in Genbank mRNAs from other mouse
tumor cell lines, suggesting that four could be unique to
CT26 cells. Three variants introduce stop codons; how-
ever all are heterozygous such that a full length gp70 can
likely be translated.
The family of cancer testes (CT) antigens has high
tumor cell selectivity. We found that CT antigens with the
highest expression in CT26 cells are known colorectal CT
antigens Casc5, Cep55 and Pbk (Table 2). These three,
along with Atad2 and Ttk, have very low expression in the
normal colon samples. Low expression of the human ho-
mologs of Casc5, Ctage5, Pbk and Spag9 has been ob-
served in multiple tissues, such that these are cancer
testes-selective antigens and they may be subject to toler-
ance [32]. Conversely, while expressed at 5-fold higher
levels in CT26 cells, Rqcd1is also expressed at significant
levels in normal colon and is thus not an ideal immuno-
therapy target.
In addition to tissue specific and over-expressed tumor
antigens, somatic mutations provide tumor-specific im-
munotherapy T-cell targets [33] that may be used for
truly individualized cancer therapeutics and vaccines
[34]. A mutation for a cancer vaccine target must be
expressed and presented on MHC molecules. Of the
3,023 CT26 point mutations, 1,172 are in expressed
genes and, of these, 154 are in epitopes predicted to
strongly bind to MHC molecules (highest 1% consensus
percentile) (Figure 1, 3rd ring). 73 occur in highly
expressed genes (at least 10 RPKM). Table 3 shows eight
such point mutations that meet these criteria. For each
SNV, Additional file 1: Table S2 lists the mutation-
containing epitope and MHC allele predicted to have
the strongest MHC binding by the IEDB algorithm [35].
Previous work by us and others [36] finds that roughly
30% of these mutations are antigenic and capable of gen-
erating a T cell response when used in immunizations.
Thus, these mutations provide a broad portfolio of po-
tentially exploitable TSAs for future studies.
Table 1 The CT26 gp70 SNVs relative to the mm9 reference genome (negative strand)
Mm9 coordinate Reference Mutation Zygosity AA change DbSNP 128 Observed in Genbank mRNAs?
chr8:125952138 T A Homo S > T rs30558843 Many, including CT26 [mRNA GU441834]
chr8:125951873 G A Hetero W > * No
chr8:125951822 A G Hetero Y > C CT26 [mRNA GU441834]
chr8:125951717 G A Hetero W > * No
chr8:125951634 G A Homo E > K CT26, B16 (melanoma), RCB0527-Jyg-MC(B) &
RCB0526-Jyg-MC(A) (mammary)
chr8:125951556 G T Hetero G > * RCB0526-Jyg-MC(A) (mammary tumor)
chr8:125951208 G A Homo G > S CT26 [mRNA GU441834]
chr8:125950710 G A Hetero E > L RCB0526-Jyg-MC(A) (mammary tumor)
chr8:125950284 G A Hetero G > R rs30722372 No
AA, amino acid; *, stop codon.
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This is the first integrated genome, transcriptome and
immunome map of a mouse epithelial tumor. We found
that the patterns of mutations in onco-relevant genes,
the gene expression signatures and the regulated path-
ways in CT26 cells are in agreement with their origin in
colon epithelia and share features with human primary
CRCs. The mutations and expression profiles are similar
to those reported for sporadic, undifferentiated, therapy-
refractory, metastasis-prone human CRC. Moreover, we
identified non-synonymous SNVs with predicted MHC
class I binding capability which, together with the robust
MHC class I expression of CT26 cells, provide a valuable
resource for use of the CT26 model system to develop
immunotherapeutic approaches.
The integrated use of mutation allele fraction and
DNA copy number allowed us to determine the absolute
copy number and zygosity for each mutation. The CT26
cells have extensive triploidy and tetraploidy and a high
mutation rate (53 non-synonymous mutations per Mb).
While Trp53, Braf, and Pik3ca are not mutated, Kras is
mutated at G12D. Similar to human CRC samples, thereTable 2 Potential CT26 T-cell tumor expression antigens
Gene CT Antigen CT26 Colon
Atad2 CT137 42.4 0.5
Casc5 CT29 10.2 0.1
Cep55 CT111 25.4 0.4
Ctage5 CT21 17.7 1.8
Dcaf12 CT102 11.4 7.8
Pbk CT84 39.6 1.0
Rqcd1 CT129 30.4 5.4
Spag9 CT89 14.7 1.2
Ttk CT96 13.1 0.3
Gp70 – 7225.4 0.0
Known CT antigens with expression above 10 RPKM in CT26 and below 10
RPKM in normal mouse colon are shown. CT26 and mouse colon expression
values are in RPKM units.is a preference for C > T/G > A transitions. However, the
CT26 mutation pattern shows a preference for C > T
mutations at sites that are followed by a pyrimidine, a
pattern that is more similar to that found in tumors
from patients pre-treated with temozolomide than to
that found in most human CRC tumors.
Clinically-approved patient selection biomarkers for
anti-EGFR treatments cetuximab and panitumumab in-
clude assessment of EGFR levels and KRAS G12D muta-
tion status. In CT26, we found the Kras G12D mutation
and no expression of Egfr. Consistent with this, CT26 cells
have been shown to be refractory to the rodent Egfr-
targeting mAbs [2]. Similarly, KRAS G12D mutations and
MAPK1 (MEK) and MET amplification are published bio-
markers for colorectal tumor sensitivity to both MEK and
MET inhibitors [3,4]. The homozygous Kras G12D muta-
tion and Mapk1 and Met amplifications in CT26 suggest
sensitivity to MEK and MET inhibition. In concordance
with this, CT26 cells have been shown to be sensitive to
MEK and MET inhibitors [2,37]. Further, the expression
of markers such as Top2a and Cldn6 and lack of expres-
sion of Muc2, Epcam and Lgals4 show that CT26 cells are
in an undifferentiated, proliferative state.Table 3 Eight potential CT26 mutation antigens that are in
genes expressed in CT26 and in epitopes predicted to bind
MHC class I molecules based on IEDB consensus ranks
Gene Mutation Epitope MHC allele
Csnk1g3 N42K VGPKFRVGKK H-2Dd
E2f8 I522T TYLQPAQAQM H-2Kd
Fam111a G213E CVYGFKEETI H-2Dd
Hdac2 P228S KYYAVNFM H-2Kd
Nudt19 L335F IYMTFPSENK H-2Kd
Phf3 G1814E FPPQNMFEF H-2Dd
Smc3 D733A KFKASRASI H-2Kd
The bold letters signify the mutated amino acid.
dThe official names of mouse MHC alleles.
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tomic analysis of one of the most frequently used cell
lines for drug development. Further, the results form the
basis for the rationale design of pre-clinical studies using
this model for drug development based on detailed mo-
lecular knowledge.
Methods
Samples: BALB/cJ mice (Charles River) were kept in ac-
cordance with legal policies on animal research at the
University of Mainz. In 2011, Germline BALB/cJ DNA
was extracted from mouse tail. CT26.WT colon carcin-
oma cells were purchased from the American Type Cul-
ture Collection (Product: ATCC CRL-2638, Lot Number:
58494154). 3rd and 4th passages of cells were used for
tumor experiments.
NGS sequencing and data processing: exome capture
from CT26 and BALB/cJ mice were sequenced in triplicate
using the Agilent Sure-Select solution-based mouse protein
coding exome capture assay. CT26 oligo(dT)-isolated RNA
for gene expression profiling was prepared in triplicate. Li-
braries were sequenced on an Illumina HiSeq2000. Protocol
details are found in the Additional file 1. DNA-derived se-
quence reads were aligned to the mm9 genome using bwa
[38] (default options, version 0.5.8c). Ambiguous reads
mapping to multiple locations of the genome were re-
moved. RNA-derived sequence reads were aligned using
bowtie [39] to the mm9 genome and RefSeq exon-exon
junctions. Default and “-v2 –best” parameters were used
for transcriptome and genome alignments, respectively.
For the exome reads, there was an average of 103 mil-
lion read pairs per sample. As each sample was sequenced
in triplicate, this resulted in over 300 million 50 nt paired-
end reads for the CT26 and BALB/cJ exomes. 83% of the
reads mapped to the mm9 reference genome, with 51% of
the nucleotides on target, resulting in a mean coverage of
170x. The CT26 transcriptome was sequenced in tripli-
cated with an average of 27 million reads and total of 81
million reads, of which 94% could be aligned. NGS read
statistics are in Additional file 1.
DNA copy number: absolute allele copy number, and
mutation allele fraction were simultaneously determined
using a novel algorithm that assumes a) that mutation
allele fraction can take only discrete values in tumor
cells based on allele copy number and b) that the relative
tumor to germline number of exome-seq reads mapping
to a gene locus is proportional to locus copy number
[40]. Copy number estimations are in Additional file 2.
Mutation identification: single nucleotide mutations
(SNVs) that were identified by all algorithms samtools
[18], Mutect [41], and SomaticSniper [42] and in the
replicates were further filtered using binomial filters that
eliminate erroneous tumor observations and decrease
the likelihood that a mutation is classified as somaticdue to lack of coverage in the germline sample. Inser-
tions and deletions (indels) were identified using sam-
tools and Varscan2 with at least 10 DNA reads support
and further filtered by removing indels with germline
support after realigning the reads to an integrated wild-
type and mutated reference genome. SNVs and indels
are in Additional files 3 and 4.
SNP detection: SNPs were detected by running the
samtools mpileup command (version 0.1.19) on sites de-
fined by dbSNP (version 128 for mm9), using the BALB/
c and CT26 exome alignments as input and binning the
results by the phred scaled SNP quality as returned by
samtools/bcftools.
Gene expression: expression values were determined by
counting reads overlapping transcript exons and junc-
tions, and normalizing to RPKM expression units (Reads
which map Per Kilobase of transcript length per Million
mapped reads). 10 RPKM is roughly the 80th percentile
(80% of the gene expression values fall below 10 RPKM).
Gene expression values are in Additional file 5.
Pathway enrichment: the ENCODE Consortium pro-
filed two normal mouse colons in triplicate using RNA-Seq
[43]; raw data were downloaded and processed through
the computational workflow used for the CT26 RNA-Seq
reads. Gene expression profiles from the triplicate CT26
and six normal mouse colon RNA-Seq runs were statis-
tically compared using a t-test. Enriched Reactome [44]
gene sets were identified using GSEA [45] and Cytos-
cape ClueGO [46] and over-expressed genes (t-test >
20). Enriched Reactome pathways are in Additional file 6.
Gene set enrichment was performed using GenePattern
[47], the Molecular Signatures Database [48], and the
expression ranked gene list. Enriched GenePattern gene
sets are listed in Additional file 7 and gene membership
is listed in Additional file 8. All identifiers were trans-
lated from mouse to human using Homologene [49].
The list of cancer testes (CT) antigens was from the
CTdatabase [50].
MHC typing and expression: typing and expression
were determined using RNA-Seq reads and the seq2HLA
algorithm [51] using the parameter setting “—best” rather
than “-a”. All mouse tissue samples were sequenced
(RNA-Seq) by us except the normal colon dataset, which
was retrieved from the ENCODE project. RNA-Seq fastq
reads were mapped according to the parameters de-
scribed in Boegel et al. [51]. Two distinct reference files
were created for BALB/c, containing reference se-
quences for H-2Dd, H-2Kd, H-2Ld and H-2Ia, and for
C57BL/6 containing reference sequences for H-2Db,H-
2Kb,H-2Iab. Expression was determined by the total
number of unique sequence reads mapping to class I or
class II genes and normalized according to reads per
kilobase of exon model per million mapped reads (RPKM)
using the length of the allele transcripts contained in the
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1102 nt, H-2Iad = 978 nt.
MHC binding: MHC binding predictions were per-
formed using the IEDB algorithm v2.5 [35], “consensus”
setting, the CT26 cell-line specific MHC type and the
identified somatic point mutations. The best neo-epitope
for a mutation was calculated as follows: all possible 8-,
9-, 10-, 11-mer peptides containing the mutated amino
acids were input to the IEDB algorithm, which predicts
the binding affinity (IC50 in nM and the consensus per-
centile rank) of the peptide to the cell line HLA alleles.
The best neo-epitope-MHC pair was defined as the pep-
tide which has the strongest predicted binding affinity to
the respective MHC allele. Epitopes with a consensus
percentile rank of less than or equal to 1% are reported
as likely immunogenic.
Availability of supplementary information
CT26 and BALB/cJ NGS fastq reads are available from
ENA as PRJEB5320 (RNA-Seq) and PRJEB5321 (Exome).
Additional files
Additional file 1: Contains supplementary methods, supplementary
tables, NGS read statistics, and the gp70 mutations and protein
sequence.
Additional file 2: Absolute copy number for each gene determined
using the number of exome-seq reads mapping to each gene from
CT26 and balb/c samples and using the allele fraction to determine
ploidy. Columns include gene, copy number, normalized ratio,
chromosome and gene start coordinate in the mm9 assembly.
Additional file 3: The 3,023 high confidence point mutations found
in CT26 transcripts. Columns include chromosomal position of the
mutation, reference and observed nt, classification non/synonymous,
classification UTR/CDS, amino acid substitution, gene symbol, transcript
ID and affected exon, mean gene expression (combined of gene
expression and exon expression), possible repeat region, dbSNP ID and
dbSNP validation source, MHC prediction for MHC class I and class II
alleles for the mutated neo-epitope and corresponding wild type pep-
tide, allele to which it is binding, percentile rank, neo-epitope sequence,
IC 50 [nM]).The mutation-containing epitope and associated MHC allele
were selected using the IEDB algorithm v2.5 [3], with consensus setting,
with the listed epitope and MHC being the pair with the predicted
strongest binding.
Additional file 4: The 363 insertion and deletion mutations.
Columns include chromosomal position of the mutation, reference and
observed nt(s), location of indel, frameshift mutation, classification non/
synonymous, in UTR, gene symbol, UCSC transcript ID (if the mutation
can occur in more than one transcript of this gene they are separated by
a space), transcript ID and affected exon, mean expression (combined of
gene expression and exon expression), possible repeat region, dbSNP ID
and dbSNP validation source, allele frequency for CT26 and Balb/c
replicates, number of reads per sample supporting this indel.
Additional file 5: Gene expression values for CT26 and ENCODE
normal mouse colon samples in RPKM values and raw read counts.
Additional file 6: Results of the GSEA gene set Reactome pathway
enrichment, including Reactome pathway name, gene membership
and FDR q-values.
Additional file 7: Results of the GenePattern enrichment using
ranked ordered expression. Gene sets included those curated fromliterature and overexpression was determined using GenePattern [4].
Gene membership and enrichment values are in the file.
Additional file 8: Contains the Gene Pattern gene set membership
and enrichment values in an html format. The file index.html is the
entry point.
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